In this phase 3 double-blind, randomized, 72-week controlled trial of 2,539 adults with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
In this phase 3 double-blind, randomized, 72-week controlled trial of 2,539 adults with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.